loqtorzi
(toripalimab-tpzi)Coherus BioSciences, Inc.
Usage: LOQTORZI is indicated for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine. It is also indicated as a single agent for adults with recurrent unresectable or metastatic NPC progressing after platinum chemotherapy.